Willis, Thomas A
Neal, Richard D
Walter, Fiona M
Foy, Robbie
Funding for this research was provided by:
National Institute for Health Research (NIHR) Policy Research Programme (PR-PRU-1217-21601)
Article History
Received: 15 May 2023
Accepted: 15 November 2023
First Online: 27 November 2023
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. The study received ethical approval from the School of Medicine Research Ethics Committee at the University of Leeds (MREC20-054). Informed consent was obtained from all participants. Panel members were offered £200 in recognition of their time and contribution.
: Not applicable.
: RN is a named joint inventor of the “PinPoint Test” that has been developed to help prioritise patients at greatest risk of cancer who are referred as a ‘two-week wait’. Should the test generate revenue then both RN and the University of Leeds stand to benefit financially. RN is also co-CI of the NHS-Galleri Trial, an RCT evaluating the benefit of a Multi-Cancer Early Detection Test. He undertakes this role through a University Consultancy through which both he and the University of Exeter benefit financially. TW, FW and RF declare that they have no competing interests.